Technical Analysis for IMM - Immupharma Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 9.7 | 4.53% | 0.42 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Historical IMM trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Slingshot Bullish | Bullish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Fell Below 50 DMA | Bearish | 4.53% | |
| Upper Bollinger Band Walk | Strength | 4.53% | |
| Multiple of Ten Bearish | Other | 4.53% | |
| Outside Day | Range Expansion | 4.53% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above 10 DMA | 1 day ago |
| 50 DMA Support | 1 day ago |
| Rose Above 50 DMA | 1 day ago |
| 20 DMA Support | 1 day ago |
| Down 3% | 1 day ago |
Free Daily (Stock) Chart Reading
Immupharma Plc Description
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Research Pain Medicine Clinic Cement Disease Earl Cancer Diseases Medical Specialties Drugs Mr Drug Discovery Disorders Autoimmune Diseases Infection Antibiotic Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 21.3909 |
| 52 Week Low | 8.1 |
| Average Volume | 1,845,499 |
| 200-Day Moving Average | 11.80 |
| 50-Day Moving Average | 9.24 |
| 20-Day Moving Average | 9.11 |
| 10-Day Moving Average | 9.47 |
| Average True Range | 0.86 |
| ADX | 34.65 |
| +DI | 16.98 |
| -DI | 8.89 |
| Chandelier Exit (Long, 3 ATRs ) | 7.91 |
| Chandelier Exit (Short, 3 ATRs ) | 10.70 |
| Upper Bollinger Band | 10.07 |
| Lower Bollinger Band | 8.16 |
| Percent B (%b) | 0.81 |
| BandWidth | 21.01 |
| MACD Line | 0.12 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.1081 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.75 | ||||
| Resistance 3 (R3) | 10.63 | 10.17 | 10.58 | ||
| Resistance 2 (R2) | 10.17 | 9.90 | 10.23 | 10.52 | |
| Resistance 1 (R1) | 9.93 | 9.73 | 10.05 | 10.05 | 10.46 |
| Pivot Point | 9.47 | 9.47 | 9.53 | 9.53 | 9.47 |
| Support 1 (S1) | 9.23 | 9.20 | 9.35 | 9.35 | 8.94 |
| Support 2 (S2) | 8.77 | 9.03 | 8.83 | 8.88 | |
| Support 3 (S3) | 8.53 | 8.77 | 8.83 | ||
| Support 4 (S4) | 8.65 |
